Verona Pharma
Focus: Verona Pharma is a UK-based public pharmaceutical company focused on small-molecule therapeutics for respiratory indications. They have launched OHTUVAYRE (ensifentrine), a phosphodiesterase 3 inhibitor, marking their entry into the commercial market.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Verona Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Verona Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Verona Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growth17.8yr
Company's only marketed NDA-approved product; represents first commercial revenue stream with long LOE runway (18+ years).
Help build intelligence for Verona Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.